Dashboard
Manage Tickers

IKTInhibikase Therapeutics, Inc.

Nasdaq inhibikase.com


$ 1.35 $ -0.02 (-1.49 %)    

Wednesday, 11-Sep-2024 15:58:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.86 $ 0.00 (0 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 555.67 $ 0.00 (0 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 1.32
$ 1.32 x 100
-- x --
-- - --
$ 0.79 - $ 3.82
35,276
na
9.85M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-27-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-lowers-price-target-to-15
HC Wainwright & Co. Maintains Buy on Inhib...
08/16/2024 09:39:29

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price ...

inhibikase-therapeutics-q2-eps-066-beats-067-estimate
Inhibikase Therapeutics Q2 EPS $(0.66) Bea...
08/14/2024 20:26:09

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-completes-enrollment-of-its-phase-2-201-trial-of-risvodetinib-in-untreated-parkinsons-disease
Inhibikase Therapeutics Completes Enrollme...
06/17/2024 12:14:36

inhibikase-therapeutics-announces-expansion-into-cardiopulmonary-disease
Inhibikase Therapeutics Announces Expansio...
06/05/2024 12:18:02

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-lowers-price-target-to-23
HC Wainwright & Co. Maintains Buy on Inhib...
05/21/2024 10:45:02

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price ...

inhibikase-therapeutics-prices-40m-registered-direct-offering-and-warrant-inducement-of-1672452-shares-of-common-stock-and-1672452-unregisted-class-b-warrants-at-combined-purchase-price-of-168-per-common-stock-and-series-a-and-b-warrant
Inhibikase Therapeutics Prices $4.0M Regis...
05/20/2024 12:07:10

inhibikase-therapeutics-q1-2024-gaap-eps-073-beats-079-estimate-cash-97m
Inhibikase Therapeutics Q1 2024 GAAP EPS $...
05/16/2024 07:06:46

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-announces-request-for-withdrawal-of-s-1-registration-statement-no-securities-have-been-sold-in-connection-with-the-offering-described-in-the-registration-statement
Inhibikase Therapeutics Announces Request ...
05/15/2024 13:13:34

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

inhibikase-therapeutics-announces-final-pre-ind-meeting-outcomes-for-ikt-001pro-for-pulmonary-arterial-hypertension
Inhibikase Therapeutics Announces Final Pr...
05/09/2024 12:52:14

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary A...

why-vaxxinity-shares-are-trading-lower-by-around-55-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Vaxxinity Shares Are Trading Lower By ...
04/22/2024 17:26:48

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
04/22/2024 16:31:48

inhibikase-therapeutics-issues-letter-to-shareholders-and-provides-update-on-development-programs-says-201-trial-is-75-enrolled
Inhibikase Therapeutics Issues Letter To S...
04/18/2024 20:37:32

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein ...

inhibikase-therapeutics-announces-apr-5-pre-ind-meeting-with-fda-for-ikt-001pro-in-pulmonary-arterial-hypertension
Inhibikase Therapeutics Announces Apr. 5 P...
04/03/2024 12:07:57

inhibikase-therapeutics-q4-eps-064-beats-085-estimate-sales-100k-down-from-6357k-yoy
Inhibikase Therapeutics Q4 EPS $(0.64) Bea...
03/28/2024 03:45:50

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate o...

inhibikase-therapeutics-fy23-eps-357-cash-position-133m-as-of-dec-31
Inhibikase Therapeutics FY23 EPS $(3.57); ...
03/27/2024 20:38:40

hc-wainwright--co-reiterates-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Inhi...
03/07/2024 16:26:19

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pr...

inhibikase-therapeutics-to-provide-trial-update-for-risvodetinib-at-the-2024-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders
Inhibikase Therapeutics To Provide Trial U...
03/07/2024 13:37:27

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

hc-wainwright--co-maintains-buy-rating-for-inhibikase-therapeutics-heres-what-you-need-to-know
HC Wainwright & Co. Maintains Buy Rating f...
03/05/2024 17:00:30

hc-wainwright--co-maintains-buy-on-inhibikase-therapeutics-maintains-27-price-target
HC Wainwright & Co. Maintains Buy on Inhib...
03/05/2024 15:50:51

HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and maintains $27 pri...

inhibikase-therapeutics-announces-full-outcomes-of-its-pre-nda-meeting-with-the-fda-for-ikt-001pro
Inhibikase Therapeutics Announces Full Out...
02/28/2024 21:51:57

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION